Amgen deploys 1,000 reps on Prolia

Amgen has deployed “500 to 1,000” reps in support of Prolia, a biologic osteoporosis treatment that received FDA approval June 1.  

Sales reps “across [Amgen's] bone health, inflammation and hospital teams” will work on the drug, calling on a “large number of physicians including specialists and primary care physicians who treat postmenopausal osteoporosis,” according to Sarah Reines, an Amgen spokesperson.

In response to a question about Prolia's positioning in the market, Reines cited “a significant clinical need in the management of postmenopausal women with osteoporosis, who are at a high risk for fracture.”

Reines said data has shown that approximately 50% of postmenopausal osteoporosis patients discontinue oral bisphosphonate therapy—such as Merck's Fosamax, Warner Chilcott's Actonel and Roche/Genentech's Boniva—within the first year. “Among patients who discontinue these treatments, many do so because of side effects, including tolerance,” Reines said. GSW Worldwide is handling the professional account out of its Columbus, Ohio headquarters.    

A twice-yearly injection, Prolia offers “robust fracture reduction at the spine, hip and other sites,” said Reines. For consumers, Amgen will “consider various platforms to educate our patients on both the condition and the product,” according to Reines. Draftfcb in New York has the consumer account.

Until recently, Prolia was known primarily by its shortened generic name, Dmab. Since at least 2008, analysts have predicted blockbuster sales, or sales over $1 billion annually, for Prolia. The drug costs $825 per 60 mg injection, and Amgen announced a ProliaPlus program, which will help interested parties sort out insurance coverage, and provide financial assistance programs.

As part of the ProliaPlus service, Amgen will “remind patients and providers about when the patient's next dose is due, thus helping to support patient adherence,” according to a statement.
You must be a registered member of MMM to post a comment.

Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.